Angelo Paradiso - Concepedia

Author

Angelo Paradiso

Also Known As

A PARADISO, A Paradiso, A V Paradiso, A. PARADISO, A. Paradiso, A. V. Paradiso, ANGELO PARADISO, ANGELO VIRGILIO PARADISO, Aldo Morrone, Angelo Paradiso

517

Publications

20.6K

Citations

H-Index

235

Concepts

All Affiliations

Istituto Tumori Bari Istituti di Ricovero e Cura a Carattere Scientifico University of Bari Aldo Moro Radiation Oncology Institute Fondazione IRCCS Istituto Nazionale dei Tumori

About

Angelo Paradiso is an author at Istituto Tumori Bari specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	34	100	3.6K
2	Engineering	9	9	266
3	Health Sciences	8	8	217
4	Natural Sciences	5	5	267
5	Nursing	1	1	17

Angelo Paradiso

188

Publications

7.9K

Citations

H-Index

Page 1

	Year	Citations
Multicenter Validation of a Gene Expression–Based Prognostic Signature in Lymph Node–Negative Primary Breast Cancer John A. Foekens, David Atkins, Yi Zhang, Journal of Clinical Oncology	2006	359
NHE1 promotes invadopodial ECM proteolysis through acidification of the peri‐invadopodial space Giovanni Busco, Rosa Angela Cardone, Maria Raffaella Greco, The FASEB Journal	2010	219
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy Yi Zhang, Anieta M. Sieuwerts, Michelle McGreevy, Breast Cancer Research and Treatment Breast OncologyOncology76-Gene SignatureEndocrine-related CancerMedicine	2008	154
Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients Angelo Paradiso, G. Simone, S. Petroni, British Journal of Cancer	2000	149
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma Simona Serratì, Michele Guida, R. Fonte, Molecular Cancer	2022	142
Cytoskeleton and paclitaxel sensitivity in breast cancer: The role of β‐tubulins Stefania Tommasi, Anita Mangia, Rosanna Lacalamita, International Journal of Cancer	2007	141
Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer Angelo Paradiso, Anita Mangia, Annalisa Chiriatti, Annals of Oncology Advanced Breast CancerBreast OncologyOncologyMedicinePathology	2005	140
Nonrandom Distribution of Aberrant Promoter Methylation of Cancer-Related Genes in Sporadic Breast Tumors Paola Parrella, Maria Luana Poeta, Antonietta Pia Gallo, Clinical Cancer Research	2004	137
DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group Sabine Maier, Inko Nimmrich, Thomas Koenig, European Journal of Cancer Tumor BiologyBreast OncologyCancer RiskMedicinePathobiology Group	2007	113
Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer Amalia Azzariti, Nicola Antonio Colabufo, Francesco Berardi, Molecular Cancer Therapeutics Breast OncologyLow SigmaChemoprevention StrategyImmunologyPharmacotherapy	2006	113

Page 1